Who
Catherine Stehman-Breen
Director
Company insider
Files Form 4 as: Director, Dyne Therapeutics; Director, Tenaya Therapeutics; Director, Generation Bio Co; SVP, Chief Medical Officer, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 3 Apr 2017
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio CoBiotechnology | SEC FORM 4 Code U | —4,752 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Co | SEC FORM 4 Code U | —4,752 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.